When follicular lymphoma undergoes histological transformation, and the patient has already received anthracycline-based therapy, treatment selection requires specific consideration. Prior anthracycline exposure is a defining factor that directly influences which regimens are most appropriate in this setting.
This protocol applies to patients with transformed follicular lymphoma who carry a history of prior anthracycline exposure. Because anthracycline re-exposure is generally avoided in this context, the available treatment strategies are shaped by that prior therapy history.
A platinum-based approach is the preferred direction for this population — the specific regimen selection, additional agents, and clinical decision pathway are detailed in the full protocol.
DOI: 10.3390/cancers18030395
Platinum-based regimens would be preferred in patients with prior anthracycline exposure, although evidence is limited to retrospective series (2C).
View source ↗